The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Chronic, controlled GDNF infusion promotes structural and functional recovery in advanced parkinsonian monkeys
Abstract
The powerful trophic effects that glial cell line-derived neurotrophic factor (GDNF) exerts on midbrain dopamine neurones suggest its use in treating Parkinson's disease. However, some important questions remain about the possible therapeutic applications of GDNF. Here we demonstrate that the chronic infusion of 5 or 15 micro g/day GDNF into the lateral ventricle or the striatum, using programmable pumps, promotes restoration of the nigrostriatal dopaminergic system and significantly improves motor functions in rhesus monkeys with neural deficits modelling the terminal stages of Parkinson's disease. The functional improvements were associated with pronounced upregulation and regeneration of nigral dopamine neurones and their processes innervating the striatum. When compared with vehicle recipients, these functional improvements were associated with (i) >30% bilateral increase in nigral dopamine neurone cell size; (ii) >20% bilateral increase in the number of nigral cells expressing the dopamine marker tyrosine hydroxylase; (iii) >70 and >50% bilateral increase in dopamine metabolite levels in the striatum and the pallidum, respectively; (iv) 233 and 155% increase in dopamine levels in the periventricular striatal region and the globus pallidus, respectively, on the lesioned side; and (v) a five-fold increase in tyrosine hydroxylase-positive fibre density in the periventricular striatal region on the lesioned side. In addition, chronic GDNF treatment did not induce the side-effects generally associated with chronic administration of levodopa, the most widely used treatment for Parkinson's disease. Thus, the results suggest that the prolonged and controlled delivery of GDNF into the brain could be used to intervene in long-term neurodegenerative disease processes like Parkinson's disease. Additional studies are required to determine the potential differences between chronic, intraventricular and intraputamenal (or intranigral) delivery of GDNF to maximize the efficacy of infusion treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wiklund, R. A., & Rosenbaum, S. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199710163371606 · Cited by 2,149
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 1,994
Uneven Pattern of Dopamine Loss in the Striatum of Patients with Idiopathic Parkinson's Disease
Kish, S. J., Shannak, K., & Hornykiewicz, O. (1988) · New England Journal of Medicine · doi:10.1056/nejm198804073181402 · Cited by 1,953
Kordower, J. H., Emborg, M. E., Bloch, J., Ma, S. Y., Chu, Y., Leventhal, L., McBride, J., Chen, E.-Y., Palfi, S., Roitberg, B. Z., et al. (2000) · Science · doi:10.1126/science.290.5492.767 · Cited by 1,251
Lang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810153391607 · Cited by 1,201
Protection and repair of the nigrostriatal dopaminergic system by GDNF in vivo
Tomac, A., Lindqvist, E., Lin, L.-F. H., Ögren, S. O., Young, D., Hoffer, B. J., & Olson, L. (1995) · Nature · doi:10.1038/373335a0 · Cited by 1,079
Functional recovery in parkinsonian monkeys treated with GDNF
Gash, D. M., Zhang, Z., Ovadia, A., Cass, W. A., Yi, A., Simmerman, L., Russell, D., Martin, D., Lapchak, P. A., Collins, F., et al. (1996) · Nature · doi:10.1038/380252a0 · Cited by 955
Self-citationDopaminergic Neurons Protected from Degeneration by GDNF Gene Therapy
Choi-Lundberg, D. L., Lin, Q., Chang, Y.-N., Chiang, Y. L., Hay, C. M., Mohajeri, H., Davidson, B. L., & Bohn, M. C. (1997) · Science · doi:10.1126/science.275.5301.838 · Cited by 625
Neurogenesis in Adult Mammals: Some Progress and Problems
Gould, E., & Gross, C. G. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-03-00619.2002 · Cited by 512
Kirik, D., Rosenblad, C., Björklund, A., & Mandel, R. J. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-12-04686.2000 · Cited by 428
Fallon, J., Reid, S., Kinyamu, R., Opole, I., Opole, R., Baratta, J., Korc, M., Endo, T. L., Duong, A., Nguyen, G., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.26.14686 · Cited by 425
Björklund, A., Kirik, D., Rosenblad, C., Georgievska, B., Lundberg, C., & Mandel, R. J. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02915-2 · Cited by 346
Anatomy of the dopamine system in the basal ganglia
Smith, Y., & Kieval, J. Z. (2000) · Trends in Neurosciences · doi:10.1016/s1471-1931(00)00023-9 · Cited by 323
Bankiewicz, K. S., Oldfield, E. H., Chiueh, C. C., Doppman, J. L., Jacobowitz, D. M., & Kopin, I. J. (1986) · Life Sciences · doi:10.1016/0024-3205(86)90431-5 · Cited by 308
Overview of morphological changes in Parkinson's disease.
Jellinger, K. A. (1987) · PubMed · Cited by 272
Tomac, A., Widenfalk, J., Lin, L. F., Kohno, T., Ebendal, T., Hoffer, B. J., & Olson, L. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.18.8274 · Cited by 258
Bensadoun, J.-C., Déglon, N., Tseng, J. L., Ridet, J.-L., Zurn, A. D., & Aebischer, P. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7409 · Cited by 184
Herkenham, M., Little, M. D., Bankiewicz, K., Yang, S.-C., Markey, S. P., & Johannessen, J. N. (1991) · Neuroscience · doi:10.1016/0306-4522(91)90180-v · Cited by 180
Imbert, C., Bézard, E., Guitraud, S., Boraud, T., & Gross, C. E. (2000) · Journal of Neuroscience Methods · doi:10.1016/s0165-0270(99)00184-3 · Cited by 163
Neuroprotective and neurorestorative properties of GDNF
Gash, D. M., Zhang, Z., & Gerhardt, G. (1998) · Annals of Neurology · doi:10.1002/ana.410440718 · Cited by 158
Self-citationRosenblad, C., Martínez-Serrano, A., & Björklund, A. (1997) · Neuroscience · doi:10.1016/s0306-4522(97)00269-8 · Cited by 154
Lindner, M. D., Winn, S. R., Baetge, E. E., Hammang, J. P., Gentile, F. T., Doherty, E., McDermott, P. E., Frydel, B. R., Ullman, M. D., Schallert, T. J., et al. (1995) · Experimental Neurology · doi:10.1016/0014-4886(95)90059-4 · Cited by 152
Zhang, Z., Miyoshi, Y., Lapchak, P. A., Collins, F., Hilt, D. C., LeBel, C. P., Kryscio, R. J., & Gash, D. M. (1997) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)36963-0 · Cited by 138
Self-citationConnor, B. J., Kozlowski, D. A., Schallert, T. J., Tillerson, J. L., Davidson, B. L., & Bohn, M. C. (1999) · Gene Therapy · doi:10.1038/sj.gt.3301033 · Cited by 135
Kirik, D., Georgievska, B., Rosenblad, C., & Björklund, A. (2001) · European Journal of Neuroscience · doi:10.1046/j.0953-816x.2001.01534.x · Cited by 133
Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys
Ovadia, A., Zhang, Z., & Gash, D. M. (1995) · Neurobiology of Aging · doi:10.1016/0197-4580(95)02012-8 · Cited by 131
Self-citationMorphological and functional effects of intranigrally administered GDNF in normal rhesus monkeys
Gash, D. M., Zhang, Z., Cass, W. A., Ovadia, A., Simmerman, L. A., Martin, D., Russell, D. A., Collins, F., Hoffer, B. J., & Gerhardt, G. A. (1995) · The Journal of Comparative Neurology · doi:10.1002/cne.903630302 · Cited by 118
Self-citationBowenkamp, K. E., David, D., Lapchak, P. A., Henry, M. A., Granholm, A.-C., Hoffer, B. J., & Mahalik, T. J. (1996) · Experimental Brain Research · doi:10.1007/bf00229549 · Cited by 110
Developing a stable bilateral model of parkinsonism in rhesus monkeys
Smith, R. D., Zhang, Z., Kurlan, R., McDermott, M., & Gash, D. M. (1993) · Neuroscience · doi:10.1016/0306-4522(93)90176-g · Cited by 104
Self-citationCass, W. A. (1996) · Journal of Neuroscience · doi:10.1523/jneurosci.16-24-08132.1996 · Cited by 100
Self-citationMiyoshi, Y., Zhang, Z., Ovadia, A., Lapchak, P. A., Collins, F., Hilt, D. C., LeBel, C. P., Kryscio, R. J., & Gash, D. M. (1997) · Annals of Neurology · doi:10.1002/ana.410420212 · Cited by 62
Self-citationCosta, S., Iravani, M. M., Pearce, R. K. B., & Jenner, P. G. (2001) · European Journal of Pharmacology · doi:10.1016/s0014-2999(00)00933-x · Cited by 56
Parkinson disease gene therapy moves toward the clinic
Björklund, A., & Lindvall, O. (2000) · Nature Medicine · doi:10.1038/81291 · Cited by 47
Emborg-Knott, M. E., & Domino, E. F. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6845 · Cited by 36
Lapchak, P. A., Araujo, D. M., Hilt, D. C., Jiao, S., Collin, F., Miyoshi, Y., Ai, Y., Zhang, Z., & Gash, D. M. (1998) · Brain Research · doi:10.1016/s0006-8993(97)01495-9 · Cited by 30
Self-citationCombating Parkinson's Disease--Step Three
Olson, L. (2000) · Science · doi:10.1126/science.290.5492.721 · Cited by 19
Grondin, R., Zhang, Z., Elsberry, D. D., Gerhardt, G. A., & Gash, D. M. (2003) · Humana Press eBooks · doi:10.1385/1-59259-142-6:257 · Cited by 14
Self-citationParkinson’s Disease. Methods and Protocols
Jellinger, K. A. (2001) · European Journal of Neurology · doi:10.1046/j.1468-1331.2001.0257h.x · Cited by 13
Kordower (1999) · doi:10.1002/1531-8249(199909)46:3
Cited by
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease
Gill, S. S., Patel, N. K., Hotton, G. R., O'Sullivan, K., McCarter, R., Bunnage, M., Brooks, D. J., Svendsen, C. N., & Heywood, P. (2003) · Nature Medicine · doi:10.1038/nm850 · Cited by 1,290
Lang, A. E., Gill, S., Patel, N. K., Lozano, A., Nutt, J. G., Penn, R., Brooks, D. J., Hotton, G., Moro, E., Heywood, P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20737 · Cited by 983
Ageing and neuronal vulnerability
Mattson, M. P., & Magnus, T. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1886 · Cited by 957
GDNF, NGF and BDNF as Therapeutic Options for Neurodegeneration
Allen, S. J., Watson, J. J., Shoemark, D. K., Barua, N. U., & Patel, N. K. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.01.004 · Cited by 820
Mattson, M. P. (2003) · NeuroMolecular Medicine · doi:10.1385/nmm:3:2:65 · Cited by 475
Metadata
- Authors
- Grondin, R., Zhang, Z., Yi, A., Cass, W. A., Maswood, N., Andersen, A. H., Elsberry, D. D., Klein, M. C., Gerhardt, G. A., & Gash, D. M.
- Venue
- Brain
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-10
- Volume
- 125
- Issue
- 10
- Pages
- 2191-2201
- ISSN
- 0006-8950 (ISSN-L)
- 1460-2156
- OpenAlex
- W2032554568
- Cited by
- 283
- References
- 39
- FWCI
- 11.72
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.